Amedeo Smart

Free Medical Literature Service

 

Amedeo

Leukemia
  Free Subscription

Articles published in
Eur J Haematol
    October 2025
  1. LIEW-LITTORIN M, Deleskog-Spangberg L, Deneberg S, Janosi J, et al
    Second- and Third-Line Salvage Chemotherapy Followed by Allogeneic Stem Cell Transplantation Leads to High Survival Rates in Primary Refractory AML-A Population-Based Study.
    Eur J Haematol. 2025;115:423-432.
    >> Share

    September 2025
  2. SRINIVASAN T, Mallik N, Sachdeva MUS, Bose P, et al
    CD48 Is a Robust Marker and a Useful Addition for Assessment of Measurable Residual Disease in T-Cell Acute Lymphoblastic Leukemia.
    Eur J Haematol. 2025 Sep 13. doi: 10.1111/ejh.70035.
    >> Share

  3. TOKUDA C, Iwasaki M, Kanda J, Kondo T, et al
    Significance of Pre- and Posttransplant Minimal Residual Disease on Transplant Outcomes in Core-Binding Factor Acute Myeloid Leukemia.
    Eur J Haematol. 2025 Sep 9. doi: 10.1111/ejh.70024.
    >> Share

  4. HANSEN MH, Gulmir R, Cedile O, Dahlmann SK, et al
    Performance of Rapid Clonotyping of Chronic Lymphocytic Leukemia Using Flongle Flow-Cell Nanopore Sequencing of IGH Rearrangements.
    Eur J Haematol. 2025 Sep 8. doi: 10.1111/ejh.70030.
    >> Share

    August 2025
  5. PALUMBO FE, Vetro C, Calafiore V, Duminuco A, et al
    Extramedullary Acute Myeloid Leukemia: Evaluating Azacitidine-Venetoclax Combination Outcomes and the Role of Molecular Genetics and Bone Marrow Involvement.
    Eur J Haematol. 2025 Aug 14. doi: 10.1111/ejh.70021.
    >> Share

  6. STEIDEL E, Orhan E, Rasche M, Pigazzi M, et al
    Prognostic Value of Molecular Genetic Measurable Residual Disease (MRD) Monitoring in Pediatric Acute Myeloid Leukemia Expressing KMT2A::MLLT10.
    Eur J Haematol. 2025 Aug 13. doi: 10.1111/ejh.70019.
    >> Share

  7. FENWARTH L, Podvin B, Vasseur L, Lebon D, et al
    Myeloid Neoplasms With Erythroid Predominance and Excess Blasts in Young Adults Exhibit Distinct Genetic Profiles.
    Eur J Haematol. 2025;115:185-192.
    >> Share

  8. BAHRAMI HEZAVEH E, Yan J, Zhao D, Wangulu C, et al
    Genetic Landscape and Risk Stratification of AML With Hyperdiploid Karyotype.
    Eur J Haematol. 2025;115:165-175.
    >> Share

    July 2025
  9. MAHAMEED B, Sharf G, Tadmor T, Kleinstern G, et al
    Gender Disparities in Health-Related Quality of Life in Patients With Chronic Lymphocytic Leukemia: Impact of Treatment Modality.
    Eur J Haematol. 2025 Jul 31. doi: 10.1111/ejh.70017.
    >> Share

    June 2025
  10. LAGANA A, Scalzulli E, Carmosino I, Bisegna ML, et al
    Treatment Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML): Analysis of Predictive Factors and Novel Baseline Scoring System to Predict Molecular Relapse.
    Eur J Haematol. 2025 Jun 30. doi: 10.1111/ejh.70006.
    >> Share

  11. BRUZZESE A, Vigna E, Martino EA, Amodio N, et al
    Treatment-Free Remission in Chronic Myeloid Leukemia: Revisiting the "W" Questions.
    Eur J Haematol. 2025 Jun 23. doi: 10.1111/ejh.70000.
    >> Share

  12. LI Y, Liu X, Li W, Hou L, et al
    Diagnostic and Prognostic Significance of Peripheral Blood RASSF1A, P16, and PTGER4 Gene Methylation in Adult Acute Leukemia.
    Eur J Haematol. 2025 Jun 3. doi: 10.1111/ejh.14442.
    >> Share

  13. KRUSZEWSKI M, Schmoor C, Berg T, Rehman UU, et al
    Sensitization of Non-M3 Acute Myeloid Leukemia Blasts to All-Trans Retinoic Acid by the LSD1 Inhibitor Tranylcypromine: TRANSATRA Phase I Study.
    Eur J Haematol. 2025 Jun 3. doi: 10.1111/ejh.14426.
    >> Share

  14. TADMOR T, Melamed G, Alapi H, Rokach L, et al
    CLLAF SCORE-A New Risk Score for Predicting Atrial Fibrillation in Treatment-Naive CLL Patients Initiating First- and Second-Generation BTK Inhibitor Therapy.
    Eur J Haematol. 2025;114:1011-1019.
    >> Share

    May 2025
  15. ALNUGHMUSH A, Alyamany R, Remberger M, Pasic I, et al
    Impact of Conditioning Intensity on Survival in Adult Patients (< 65 Years) With Acute Myeloid Leukemia Receiving Antithymocyte Globulin and Post-Transplantation Cyclophosphamide Based GVHD Prophylaxis.
    Eur J Haematol. 2025 May 28. doi: 10.1111/ejh.14438.
    >> Share

  16. KOCKEROLS C, Valk PJM, Hogenbirk P, Geelen I, et al
    Treatment-Free Remission Outcomes in a BCR::ABL1 Digital PCR Selected Clinical Cohort of CML Patients.
    Eur J Haematol. 2025;114:900-907.
    >> Share

    April 2025
  17. FRISCH A, Ganzel C, Ofran Y, Krayem B, et al
    Post-Relapse Outcomes of Older Patients With NPM1-Mutated AML Are Favorable With Allo Transplant in Second Remission.
    Eur J Haematol. 2025;114:641-649.
    >> Share

    March 2025
  18. LOHRBERG M, Heber M, Ries L, Markus K, et al
    Dual Targeting of Pim and PI3 Kinases in Mature T-Cell Lymphoma.
    Eur J Haematol. 2025 Mar 31. doi: 10.1111/ejh.14420.
    >> Share

  19. CHEN D, Cantu M, Siddon A, Weinberg OK, et al
    TP53-Mutated Acute Myeloid Leukemia and Blast Phase Myeloproliferative Neoplasm: Distinct Mutation Leads to Poorer Prognosis.
    Eur J Haematol. 2025 Mar 28. doi: 10.1111/ejh.14421.
    >> Share

  20. POONSOMBUDLERT K, Yodsuwan R, Mott S, Crawford K, et al
    Effect of NPM1 Mutation Subtype and Co-Mutation Patterns on the Outcomes of Acute Myeloid Leukemia.
    Eur J Haematol. 2025 Mar 19. doi: 10.1111/ejh.14415.
    >> Share

  21. ZHENG R, Gagan JR, Botten GA, Koduru P, et al
    Genomic Landscape of Mixed Phenotype Acute Leukemia Associated With Immunophenotypic Lineage Predominance: Impact on Diagnosis and Treatment.
    Eur J Haematol. 2025 Mar 18. doi: 10.1111/ejh.14414.
    >> Share

  22. CHUNG C, Doan D
    Targeting the Immune Microenvironment in Chronic Lymphocytic Leukemia: An Evolving Therapeutic Strategy.
    Eur J Haematol. 2025 Mar 11. doi: 10.1111/ejh.14408.
    >> Share

  23. NAGAFUJI K, Ito Y, Miyamoto T, Eto T, et al
    Clinical Impact of Continuous Dasatinib Administration on the Prognosis of Patients With BCR::ABL1 Acute Lymphoblastic Leukemia: Result of the Prospective MRD2014 Study Conducted by Fukuoka Blood and Marrow Transplantation Group (FBMTG).
    Eur J Haematol. 2025 Mar 7. doi: 10.1111/ejh.14407.
    >> Share

  24. BRUZZESE A, Martino EA, Labanca C, Carida G, et al
    Therapeutic Strategies for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients: Optimizing the Use of Monoclonal Antibodies.
    Eur J Haematol. 2025 Mar 6. doi: 10.1111/ejh.14405.
    >> Share

  25. GHIMIRE B, Zimmer M, Donthireddy V
    TP53-Mutated Acute Myeloid Leukemia: Review of Treatment and Challenges.
    Eur J Haematol. 2025 Mar 4. doi: 10.1111/ejh.14404.
    >> Share

    February 2025
  26. VEYHE SR, Hansen MH, Cedile O, Moller MB, et al
    A Case-Driven Multi-Omics Analysis for Longitudinal Ibrutinib Response Evaluation of Patients With Chronic Lymphocytic Leukemia.
    Eur J Haematol. 2025 Feb 23. doi: 10.1111/ejh.14397.
    >> Share

  27. CASTELLET H, Ramil G, Carricondo M, Onate G, et al
    Measurable Residual Disease in UBTF-TD Adult Acute Myeloid Leukemia.
    Eur J Haematol. 2025 Feb 23. doi: 10.1111/ejh.14402.
    >> Share

  28. ROBAK T, Robak M, Majchrzak A, Krawczynska A, et al
    Atypical Hairy Cell Leukemia-The Current Status and Future Directions.
    Eur J Haematol. 2025 Feb 10. doi: 10.1111/ejh.14388.
    >> Share

  29. BENOIT TM, Bachofner A, Wolfensberger N, Zaugg-Berger Y, et al
    Inferior Overall Survival After Haploidentical Donor Lymphocyte Infusions in Relapsed Myeloid Neoplasms.
    Eur J Haematol. 2025;114:315-324.
    >> Share

  30. BRESSER H, Schmoor C, Grishina O, Pfeifer D, et al
    Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to Decitabine.
    Eur J Haematol. 2025;114:231-237.
    >> Share

    January 2025
  31. HYPPOLITO JE, Arcuri LJ, Vicente A, Farnese V, et al
    Central Nervous System Involvement in Chronic Lymphocytic Leukemia: A Case-Series.
    Eur J Haematol. 2025 Jan 31. doi: 10.1111/ejh.14389.
    >> Share

  32. YANG MM, Singh R, Haugen M, Duff A, et al
    Adherence to 6-Mercaptopurine (6-MP) and Habit Strength in Pediatric Acute Lymphoblastic Leukemia (ALL).
    Eur J Haematol. 2025 Jan 20. doi: 10.1111/ejh.14386.
    >> Share

  33. ZALAPA-SOTO J, Rios-Olais FA, Chacon-Rangel LC, Mora-Canas A, et al
    Hyper-CVAD and Modified CALGB-10403 Regimens in Adult Patients With Philadelphia-Negative Acute Lymphoblastic Leukemia: A Comparative Study.
    Eur J Haematol. 2025 Jan 7. doi: 10.1111/ejh.14381.
    >> Share

  34. BRUZZESE A, Martino EA, Labanca C, Mendicino F, et al
    Advances and Challenges in Quizartinib-Based FLT3 Inhibition for Acute Myeloid Leukemia: Mechanisms of Resistance and Prospective Combination Therapies.
    Eur J Haematol. 2025 Jan 6. doi: 10.1111/ejh.14383.
    >> Share

  35. BERTON G, Hospital MA, Garciaz S, Rouzaud C, et al
    Outcomes of Elderly Patients Admitted to the Intensive Care Unit for Newly Diagnosed Acute Myeloid Leukemia.
    Eur J Haematol. 2025 Jan 6. doi: 10.1111/ejh.14366.
    >> Share

  36. JENSEN ABH, Andersen HRP, Jensen ST, Jensen CF, et al
    Musculoskeletal Symptoms and Misdiagnoses in Children With Acute Myeloid Leukaemia: A Nationwide Cohort Study.
    Eur J Haematol. 2025;114:57-69.
    >> Share

    December 2024
  37. PUCKRIN R, Owen C, Peters A
    Underrepresentation of Small Lymphocytic Lymphoma in Clinical Trials for Chronic Lymphocytic Leukemia.
    Eur J Haematol. 2024 Dec 27. doi: 10.1111/ejh.14376.
    >> Share

  38. TANG MW, Van der Tuin D, Aydin M, Heijmans J, et al
    Comparison of HiDAC Versus FLAG-IDA in the Treatment of Relapsed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome.
    Eur J Haematol. 2024 Dec 26. doi: 10.1111/ejh.14370.
    >> Share

  39. ROWE M, Babushok D, Carroll M, Carulli A, et al
    Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen.
    Eur J Haematol. 2024 Dec 26. doi: 10.1111/ejh.14371.
    >> Share

    November 2024
  40. MORT JF, Brighton D, DiBenedetto S, Wells L, et al
    Evaluation of Gemtuzumab Ozogamicin and Anthracycline Dosing for Favorable Risk Acute Myeloid Leukemia.
    Eur J Haematol. 2024 Nov 27. doi: 10.1111/ejh.14354.
    >> Share

  41. YALNIZ FF, Johnson A, Alnimer Y, Chahine Z, et al
    Unveiling the Genetic and Clinical Differences of Acute Myeloid Leukemia (AML) in Obese Patients.
    Eur J Haematol. 2024 Nov 13. doi: 10.1111/ejh.14338.
    >> Share

  42. CHEN EY, Dahlen T, Stenke L, Bjorkholm M, et al
    Loss in Overall and Quality-Adjusted Life Expectancy for Patients With Chronic-Phase Chronic Myeloid Leukemia.
    Eur J Haematol. 2024 Nov 6. doi: 10.1111/ejh.14328.
    >> Share

  43. SMITH E, Atenafu EG, Bankar A, Chan S, et al
    Evolution from an antecedent chronic myeloid malignancy does not impact survival outcomes in NPM1-mutated AML.
    Eur J Haematol. 2024;113:716-726.
    >> Share

    October 2024
  44. SHACHAM-ABULAFIA A, Volcheck Y, Ellis M, Shapira S, et al
    Asciminib in Advanced-Line Treatment of Chronic Myeloid Leukemia.
    Eur J Haematol. 2024 Oct 21. doi: 10.1111/ejh.14330.
    >> Share

  45. BRUZZESE A, Martino EA, Labanca C, Mendicino F, et al
    Therapy-Related Acute Promyelocytic Leukemia: Case Series and Current Insights.
    Eur J Haematol. 2024 Oct 13. doi: 10.1111/ejh.14327.
    >> Share

    September 2024
  46. MURRAY GF, Bouligny IM, Ho T, Gor J, et al
    Clonal Evolution in 207 Cases of Refractory or Relapsed Acute Myeloid Leukemia.
    Eur J Haematol. 2024 Sep 24. doi: 10.1111/ejh.14308.
    >> Share

  47. STEINER N, Massoud R, Richter J, Perekhrestenko T, et al
    Comparable Results Between 8 and 12 Gray TBI in Combination With Fludarabine and Post-Transplant Cyclophosphamide in MRD-Negative but Not in MRD-Positive Acute Lymphoblastic Leukemia Patients Transplanted in First Complete Remission.
    Eur J Haematol. 2024 Sep 19. doi: 10.1111/ejh.14305.
    >> Share

  48. BUCELLI C, Capodanno I, Miggiano MC, Cavazzini F, et al
    Choice of Frontline Tyrosine-Kinase Inhibitor and Early Events in Very Elderly Patients With Chronic Myeloid Leukemia in Chronic Phase: A "Campus CML" Study.
    Eur J Haematol. 2024 Sep 12. doi: 10.1111/ejh.14299.
    >> Share

  49. WILLE K, Dumke M, Wilsdorf N, Sadjadian P, et al
    Venetoclax Combined With FLAG-IDA in Refractory or Relapsed Acute Myeloid Leukemia.
    Eur J Haematol. 2024 Sep 9. doi: 10.1111/ejh.14302.
    >> Share

  50. ISHIKAWA C, Mori N
    A New Strategy for Adult T-Cell Leukemia Treatment Targeting Glycogen Synthase Kinase-3beta.
    Eur J Haematol. 2024 Sep 6. doi: 10.1111/ejh.14300.
    >> Share

  51. LIN S, Liao N, Li X, Yang L, et al
    Prognosis of pediatric BCP-ALL with IKZF1 deletions and impact of intensive chemotherapy: Results of SCCLG-2016 study.
    Eur J Haematol. 2024;113:357-370.
    >> Share

    August 2024
  52. SOUA A, Gilhodes J, Iat A, Hicheri Y, et al
    Venetoclax-based non-intensive induction followed by allogenic stem-cell transplantation in elderly acute myeloid leukemia patients with adverse cytogenetics.
    Eur J Haematol. 2024 Aug 11. doi: 10.1111/ejh.14290.
    >> Share

    July 2024
  53. RANTI J, Pudas H, Ranta M, Tuominen S, et al
    Treatment and clinical outcomes of patients with acute myeloid leukemia in Finland 2010-2020: A retrospective analysis of electronic health records.
    Eur J Haematol. 2024 Jul 29. doi: 10.1111/ejh.14272.
    >> Share

  54. ACKER F, Chromik J, Tiedjen E, Wolf S, et al
    Real-world effectiveness of first-line azacitidine or decitabine with or without venetoclax in acute myeloid leukemia patients unfit for intensive therapy.
    Eur J Haematol. 2024 Jul 18. doi: 10.1111/ejh.14278.
    >> Share

  55. KOCKEROLS C, Valk PJM, Janssen JJWM, Hogenbirk P, et al
    Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR::ABL1 digital PCR in chronic myeloid leukemia patients.
    Eur J Haematol. 2024 Jul 12. doi: 10.1111/ejh.14271.
    >> Share

  56. LINES M, Kemper RM, Wallace J, Alexander T, et al
    Use of allopurinol to manage skewed 6-mercaptopurine metabolism in pediatric maintenance acute lymphoblastic leukemia treatment.
    Eur J Haematol. 2024 Jul 11. doi: 10.1111/ejh.14273.
    >> Share

  57. GUEUNING C, Lazaro E, Dupuy H, Leonard C, et al
    Characteristics of large granular lymphocyte leukemia associated with variable common immunodeficiency disorders: A study of 12 cases.
    Eur J Haematol. 2024 Jul 10. doi: 10.1111/ejh.14265.
    >> Share

    June 2024
  58. SKIPPER MT, Birkebaek N, Jensen RB, Rank CU, et al
    Pancreas-related persisting sequelae in ALL survivors with a history of asparaginase-associated pancreatitis: A part of the ALL-STAR study.
    Eur J Haematol. 2024;112:944-956.
    >> Share

  59. GERHARDT A, Dorfel S, Schulz H, Schlag R, et al
    Outcomes with ibrutinib in patients with chronic lymphocytic leukaemia: Results from the German multicentre REALITY study.
    Eur J Haematol. 2024;112:927-937.
    >> Share

  60. KUTSCH N, Godel P, Voltin CA, Hallek M, et al
    Long-term remission in a patient with relapsed Richter's transformation treated with CD19-directed chimeric antigen-receptor T-cells after allogeneic stem cell transplantation.
    Eur J Haematol. 2024;112:984-987.
    >> Share

    May 2024
  61. TAGHILOO S, Asgarian-Omran H
    Cross-talk between leukemic and immune cells at the tumor microenvironment in chronic lymphocytic leukemia: An update review.
    Eur J Haematol. 2024 May 2. doi: 10.1111/ejh.14224.
    >> Share

  62. KUTSCH N, Giza A, Robrecht S, Stumpf J, et al
    Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registry.
    Eur J Haematol. 2024 May 1. doi: 10.1111/ejh.14220.
    >> Share

    April 2024
  63. AFTANDILIAN C, Bito XR, Berman D, Zhang A, et al
    Plasma microbial cell-free DNA following chimeric antigen receptor T cell therapy in pediatric patients with relapsed/refractory leukemia.
    Eur J Haematol. 2024 Apr 24. doi: 10.1111/ejh.14216.
    >> Share

  64. MARRA JD, Galli E, Giammarco S, Metafuni E, et al
    CAR-T from cord blood in a patient with Ph+ acute lymphoblastic leukemia relapsing after hematopoietic stem cell transplantation.
    Eur J Haematol. 2024 Apr 21. doi: 10.1111/ejh.14217.
    >> Share

  65. MIKLOS E, Oliver TP, Adam K, Eva K, et al
    Fix low dose venetoclax-azacitidine treatment of unfit acute myeloid leukemia patients.
    Eur J Haematol. 2024 Apr 21. doi: 10.1111/ejh.14213.
    >> Share

  66. GRONLUND JK, Veigaard C, Juhl-Christensen C, Skou AS, et al
    Droplet digital PCR for sensitive relapse detection in acute myeloid leukaemia patients transplanted by reduced intensity conditioning.
    Eur J Haematol. 2024;112:601-610.
    >> Share

  67. DELANOTE V, Callens R, Vogelaers D, Deeren D, et al
    Screening for multidrug-resistant organisms in high-risk hospitalized patients with hematologic diseases.
    Eur J Haematol. 2024;112:627-632.
    >> Share

  68. PETIT C, Saillard C, Mohty B, Hicheri Y, et al
    Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients.
    Eur J Haematol. 2024;112:530-537.
    >> Share

  69. ISHIKAWA C, Mori N
    Pivotal role of dihydroorotate dehydrogenase as a therapeutic target in adult T-cell leukemia.
    Eur J Haematol. 2024 Apr 1. doi: 10.1111/ejh.14209.
    >> Share

    March 2024
  70. POONSOMBUDLERT K, Mott S, Miller B, Dhakal P, et al
    Transplant versus no transplant in myelodysplastic syndrome and acute myeloid leukemia with TP53 mutation; a referral center experience.
    Eur J Haematol. 2024 Mar 21. doi: 10.1111/ejh.14199.
    >> Share

  71. ZHANG X, Zhang K, Zhang J, Chang W, et al
    DNMTs-mediated SOCS3 methylation promotes the occurrence and development of AML.
    Eur J Haematol. 2024;112:439-449.
    >> Share

  72. GARCIA-POUTON N, Ortiz-Maldonado V, Peyrony O, Chumbita M, et al
    Infection epidemiology in relation to different therapy phases in patients with haematological malignancies receiving CAR T-cell therapy.
    Eur J Haematol. 2024;112:371-378.
    >> Share

    February 2024
  73. GAO J, Santana-Santos L, Fu L, Alvey E, et al
    Clinical implications of additional chromosomal abnormalities in adult acute myeloid leukemia with inv (16)/t(16;16)/CBFB::MYH11.
    Eur J Haematol. 2024 Feb 22. doi: 10.1111/ejh.14192.
    >> Share

  74. SUN Y, Zhu G, Zhong H
    Minimal residual disease monitoring in acute myeloid leukemia: Focus on MFC-MRD and treatment guidance for elderly patients.
    Eur J Haematol. 2024 Feb 11. doi: 10.1111/ejh.14187.
    >> Share

  75. MELLINGHOFF SC, Robrecht S, Sprute R, Mayer L, et al
    Hybrid immunity to SARS-CoV-2 in patients with chronic lymphocytic leukemia.
    Eur J Haematol. 2024 Feb 4. doi: 10.1111/ejh.14170.
    >> Share

  76. INFANTE JB, Esteves GV, Raposo J, de Lacerda JF, et al
    Disseminated intravascular coagulation score evolution in 48 h predicts early death in acute promyelocytic leukemia patients.
    Eur J Haematol. 2024 Feb 2. doi: 10.1111/ejh.14177.
    >> Share

  77. SEVOYAN A, Mekinian A, Chermat F, Ades L, et al
    MDS/CMML from resource-limited region: Characteristics and comparison to tertiary reference European center.
    Eur J Haematol. 2024;112:296-300.
    >> Share

    January 2024
  78. WIESEN MHJ, Stemler J, Fietz C, Joisten C, et al
    Quantification of midostaurin in plasma and serum by stable isotope dilution liquid chromatography-tandem mass spectrometry: Application to a cohort of patients with acute myeloid leukemia.
    Eur J Haematol. 2024 Jan 31. doi: 10.1111/ejh.14178.
    >> Share

  79. PODGORICA M, Drivet E, Viken JK, Richman A, et al
    Transcriptome analysis of primary adult B-cell lineage acute lymphoblastic leukemia identifies pathogenic variants and gene fusions, and predicts subtypes for in depth molecular diagnosis.
    Eur J Haematol. 2024 Jan 8. doi: 10.1111/ejh.14164.
    >> Share

  80. MOYEN TB, Tomaz V, Campregher PV
    Feasibility, accuracy, and usability analysis of MapAML, a first-in-class app for integrated diagnosis in acute myeloid leukemia.
    Eur J Haematol. 2024 Jan 3. doi: 10.1111/ejh.14158.
    >> Share

  81. GUPTA S, Kohorst M, Alkhateeb HB
    Determinants of outcomes and advances in CD19-directed chimeric antigen receptor therapy for B-cell acute lymphoblastic leukemia.
    Eur J Haematol. 2024;112:51-63.
    >> Share

  82. WANG XY, Bian MR, Lin GQ, Yu L, et al
    Tandem bispecific CD123/CLL-1 CAR-T cells exhibit specific cytolytic effector functions against human acute myeloid leukaemia.
    Eur J Haematol. 2024;112:83-93.
    >> Share

  83. JI Q, Wu X, Zhang Y, Zeng L, et al
    Adverse events and efficacy of second-round CAR-T cell therapy in relapsed pediatric B-ALL.
    Eur J Haematol. 2024;112:75-82.
    >> Share

  84. KHAN AN, Asija S, Pendhari J, Purwar R, et al
    CAR-T cell therapy in hematological malignancies: Where are we now and where are we heading for?
    Eur J Haematol. 2024;112:6-18.
    >> Share

    December 2023
  85. TAMEFUSA K, Ochi M, Ishida H, Shiwaku T, et al
    Delayed diagnostic interval and survival outcomes in pediatric leukemia: A single-center, retrospective study.
    Eur J Haematol. 2023 Dec 28. doi: 10.1111/ejh.14162.
    >> Share

  86. MORI T, Osumi T, Kada A, Ohki K, et al
    Rituximab with standard LMB chemotherapy in pediatric high-risk mature B-cell non-Hodgkin lymphoma: A report from the JPLSG B-NHL14 trial.
    Eur J Haematol. 2023 Dec 19. doi: 10.1111/ejh.14148.
    >> Share

  87. NEUMANN MA, Nieper P, Simon F, Shimabukuro-Vornhagen A, et al
    A diagnostic challenge-First case of chronic lymphatic leukemia-associated necrotizing sweet syndrome.
    Eur J Haematol. 2023 Dec 17. doi: 10.1111/ejh.14153.
    >> Share

  88. COSTA A, Carmosino I, Scalzulli E, Minotti C, et al
    Early death risk score in acute promyelocytic leukemia: A retrospective analysis from a monocentric cohort.
    Eur J Haematol. 2023 Dec 14. doi: 10.1111/ejh.14155.
    >> Share

  89. LAGANA A, Pepe S, Scalzulli E, Carmosino I, et al
    One-month qRT-PCR BCR::ABL1 transcript threshold to predict early recurrence in chronic phase CML patients attempting first treatment free remission.
    Eur J Haematol. 2023;111:970-972.
    >> Share

    November 2023
  90. NEVEJAN L, Labarque V, Boeckx N
    Chronic myeloid leukemia (CML) in children and adolescents-Clinicopathological findings.
    Eur J Haematol. 2023 Nov 20. doi: 10.1111/ejh.14137.
    >> Share

  91. LEE BJ, Griffin SP, Doh J, Chan A, et al
    HyperCVAD versus pegaspargase-containing regimens for Hispanic adults with newly diagnosed B-cell acute lymphoblastic leukemia.
    Eur J Haematol. 2023 Nov 6. doi: 10.1111/ejh.14125.
    >> Share

    October 2023
  92. SEGHATOL-ESLAMI VC, Cook EW 3rd, Sharafeldin N, Wolfson J, et al
    Adaptive functioning and academic achievement in pediatric survivors of acute lymphoblastic leukemia: Associations with executive functioning, socioeconomic status, and academic support.
    Eur J Haematol. 2023 Oct 5. doi: 10.1111/ejh.14112.
    >> Share

  93. KRISTENSEN DT, Brondum RF, Orskov AD, Marcher CW, et al
    Venetoclax-based therapy for relapsed or refractory acute myeloid leukaemia following intensive induction chemotherapy.
    Eur J Haematol. 2023;111:573-582.
    >> Share

  94. MIYAJIMA T, Onozawa M, Yoshida S, Miyashita N, et al
    Clinical implications of NUP98::NSD1 fusion at diagnosis in adult FLT3-ITD positive AML.
    Eur J Haematol. 2023;111:620-627.
    >> Share

  95. BREINHOLT MF, Schejbel L, Gang AO, Nielsen TH, et al
    Next generation sequencing in routine diagnostics of mature non-Hodgkin's B-cell lymphomas.
    Eur J Haematol. 2023;111:583-591.
    >> Share

    September 2023
  96. AGRAWAL V, Murphy L, Pourhassan H, Pullarkat V, et al
    Optimizing CAR-T cell therapy in adults with B-cell acute lymphoblastic leukemia.
    Eur J Haematol. 2023 Sep 29. doi: 10.1111/ejh.14109.
    >> Share

  97. KOCKEROLS C, Valk PJM, Blijlevens NMA, Cornelissen JJ, et al
    BCR::ABL1 kinase domain mutation testing and clinical outcome in a nationwide chronic myeloid leukemia patient population.
    Eur J Haematol. 2023 Sep 20. doi: 10.1111/ejh.14107.
    >> Share

  98. CHATTERJEE G, Dhende P, Raj S, Shetty V, et al
    15-color highly sensitive flow cytometry assay for post anti-CD19 targeted therapy (anti-CD19-CAR-T and blinatumomab) measurable residual disease assessment in B-lymphoblastic leukemia/lymphoma: Real-world applicability and challenges.
    Eur J Haematol. 2023 Sep 14. doi: 10.1111/ejh.14102.
    >> Share

  99. ZARLING LC, Stevenson PA, Soma LA, Martino CH, et al
    Hyper-CVAD versus dose-adjusted EPOCH as initial treatment for adults with acute lymphoblastic leukemia.
    Eur J Haematol. 2023 Sep 5. doi: 10.1111/ejh.14089.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016